Background: Atazanavir and lopinavir represent the main HIV protease inhibitors recommended in pregnancy, but comparative data in pregnant women are limited. Methods: Women from a national observational study, exposed in pregnancy to either atazanavir or lopinavir, were compared for glucose and lipid profiles, liver function tests, CD4 count, HIV RNA and main pregnancy outcomes. Statistical methods included univariate and multivariable analyses. Results: The study population included 428 pregnancies (lopinavir, 322; atazanavir, 106). The lopinavir group was characterized by higher rates of HIV diagnosis in pregnancy and treatment indication for maternal health, lower CD4 counts, higher HIV RNA levels, less frequent antiretroviral treatment at conception and shorter duration of drug exposure during pregnancy. No differences in pregnancy outcomes, glucose metabolism and weight gain were observed. The two groups also showed in a multivariable analysis similar odds for detectable HIV RNA in the third trimester (adjusted OR 0.85, 95% CI 0.35-2.10, P1/40.730). Total lipid levels were significantly higher in the lopinavir group (median values in the third trimester 239 versus 221 mg/dL for total cholesterol and 226 versus 181 mg/dL for triglycerides; P<0.001 for both comparisons) and bilirubin levels were significantly higher in the atazanavir group (1.53 versus 0.46 mg/dL, P<0.001). Conclusions: In this observational study atazanavir and lopinavir showed similar safety and activity in pregnancy, with no differences in the main pregnancy outcomes. Atazanavir usewas associated with a better lipid profile and with higher bilirubin levels. Overall, the study findings confirm that these two HIV protease inhibitors represent equally valid alternative options.

Atazanavir and lopinavir profile in pregnant women with HIV : tolerability, activity and pregnancy outcomes in an observational national study / M. Floridia, M. Ravizza, G. Masuelli, V. Giacomet, P. Martinelli, A.D. Antoni, A. Spinillo, M. Fiscon, D. Francisci, G. Liuzzi, C. Pinnetti, A.M. Marconi, E. Tamburrini, F. Mori, P. Ortolani, E.R. Dalle Nogare, F. Di Lorenzo, G. Sterrantino, M. Meli, S. Polemi, J. Nocentini, M. Baldini, G. Montorzi, M. Mazzetti, P. Rogasi, B. Borchi, F. Vichi, B. Del Pin, E. Pinter, E. Anzalone, R. Marocco, C. Mastroianni, V.S. Mercurio, A. Carocci, E. Grilli, A. Maccabruni, M. Zaramella, B. Mariani, G. Natalini Raponi, G. Guaraldi, G. Nardini, C. Stentarelli, B. Beghetto, A.M. Degli Antoni, A. Molinari, M.P. Crisalli, A. Donisi, M. Piepoli, V. Cerri, G. Zuccotti, V. Giacomet, V. Fabiano, G. Placido, A. Vivarelli, P. Castelli, F. Savalli, V. Portelli, F. Sabbatini, D. Francisci, L. Bernini, P. Grossi, L. Rizzi, S. Alberico, G. Maso, M. Airoud, G. Soppelsa, A. Meloni, M. Dedoni, C. Cuboni, F. Ortu, P. Piano, A. Citernesi, I. Bordoni Vicini, K. Luzi, M. Roccio, A. Vimercati, A. Miccolis, E. Bassi, B. Guerra, F. Cervi, C. Puccetti, P. Murano, M. Contoli, M.G. Capretti, C. Marsico, G. Faldella, M. Sansone, P. Martinelli, A. Agangi, C. Tibaldi, L. Trentini, T. Todros, G. Masuelli, V. Frisina, I. Cetin, T. Brambilla, V. Savasi, C. Personeni, C. Giaquinto, M. Fiscon, R. Rinaldi, E. Rubino, A. Bucceri, R. Matrone, G. Scaravelli, C. Fundarò, O. Genovese, C. Cafforio, C. Pinnetti, G. Liuzzi, V. Tozzi, P. Massetti, A.M. Casadei, A.F. Cavaliere, V. Finelli, M. Cellini, G. Castelli Gattinara, A.M. Marconi, S. Dalzero, V. Sacchi, A. De Pirro, C. Polizzi, A. Mattei, M.F. Pirillo, R. Amici, C.M. Galluzzo, S. Baroncelli, S. Donnini. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - 69:5(2014), pp. dkt497.1377-dkt497.1384. [10.1093/jac/dkt497]

Atazanavir and lopinavir profile in pregnant women with HIV : tolerability, activity and pregnancy outcomes in an observational national study

V. Giacomet;A.M. Marconi;A. Molinari;G. Zuccotti
Membro del Collaboration Group
;
V. Giacomet;V. Fabiano;F. Savalli
Membro del Collaboration Group
;
L. Bernini;L. Rizzi
Membro del Collaboration Group
;
A. Meloni
Membro del Collaboration Group
;
M. Sansone;I. Cetin
Membro del Collaboration Group
;
V. Savasi
Membro del Collaboration Group
;
C. Personeni
Membro del Collaboration Group
;
C. Cafforio
Membro del Collaboration Group
;
A.M. Marconi;S. Dalzero
Membro del Collaboration Group
;
A. Mattei
Membro del Collaboration Group
;
S. Donnini;F. Parazzini;S. Vella;
2014

Abstract

Background: Atazanavir and lopinavir represent the main HIV protease inhibitors recommended in pregnancy, but comparative data in pregnant women are limited. Methods: Women from a national observational study, exposed in pregnancy to either atazanavir or lopinavir, were compared for glucose and lipid profiles, liver function tests, CD4 count, HIV RNA and main pregnancy outcomes. Statistical methods included univariate and multivariable analyses. Results: The study population included 428 pregnancies (lopinavir, 322; atazanavir, 106). The lopinavir group was characterized by higher rates of HIV diagnosis in pregnancy and treatment indication for maternal health, lower CD4 counts, higher HIV RNA levels, less frequent antiretroviral treatment at conception and shorter duration of drug exposure during pregnancy. No differences in pregnancy outcomes, glucose metabolism and weight gain were observed. The two groups also showed in a multivariable analysis similar odds for detectable HIV RNA in the third trimester (adjusted OR 0.85, 95% CI 0.35-2.10, P1/40.730). Total lipid levels were significantly higher in the lopinavir group (median values in the third trimester 239 versus 221 mg/dL for total cholesterol and 226 versus 181 mg/dL for triglycerides; P<0.001 for both comparisons) and bilirubin levels were significantly higher in the atazanavir group (1.53 versus 0.46 mg/dL, P<0.001). Conclusions: In this observational study atazanavir and lopinavir showed similar safety and activity in pregnancy, with no differences in the main pregnancy outcomes. Atazanavir usewas associated with a better lipid profile and with higher bilirubin levels. Overall, the study findings confirm that these two HIV protease inhibitors represent equally valid alternative options.
pre-term delivery; HIV RNA; cholesterol; triglycerides; bilirubin
Settore MED/38 - Pediatria Generale e Specialistica
Settore MED/40 - Ginecologia e Ostetricia
2014
Article (author)
File in questo prodotto:
File Dimensione Formato  
J. Antimicrob. Chemother.-2014-Floridia-1377-84.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 240.53 kB
Formato Adobe PDF
240.53 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/239393
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 9
social impact